Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects With Moderate to Severe Hidradenitis Suppurativa

Trial Profile

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects With Moderate to Severe Hidradenitis Suppurativa

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2019

At a glance

  • Drugs Guselkumab (Primary) ; Guselkumab (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Proof of concept; Therapeutic Use
  • Acronyms NOVA
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 24 Jan 2019 Planned End Date changed from 4 Dec 2020 to 29 Oct 2020.
    • 28 Nov 2018 Planned End Date changed from 16 Nov 2020 to 4 Dec 2020.
    • 31 Oct 2018 Planned End Date changed from 13 Nov 2020 to 16 Nov 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top